MaxCyte, Inc.
MaxCyte, Inc. scores highest on Nitro (75) and lowest on Anchor (36). Its PosiPenta is 52.65 out of 100, around the middle of similar companies.
On the Penta Grid this week, MaxCyte, Inc. is Grid #239 of 837 in the Healthcare sector in United States, and Grid #1,566 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| MaxCyte, Inc. | 52.65 | 41 | 54 | 75 | 57 | 36 |
| Canton Strategic Holdings, Inc. | 51.30 | 48 | 73 | 18 | 71 | 47 |
| Acumen Pharmaceuticals, Inc. | 36.92 | 27 | 33 | 40 | 26 | 58 |
| Compass Therapeutics, Inc. | 39.34 | 40 | 39 | 13 | 51 | 54 |
| Protara Therapeutics, Inc. | 36.30 | 41 | 29 | 13 | 61 | 38 |
| Journey Medical Corporation | 45.77 | 15 | 69 | 45 | 43 | 56 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.82 |
| P/B ratio | 0.85 |
EEarnings
| Trailing EPS | ₹-32.20 |
| Forward EPS | ₹-23.36 |
NNitro
| Price | 123.13 |
| 52-week high | 170.96 |
| 52-week low | 60.90 |
| Fall from 52-week high | 28.0% |
TTorque
| Return on equity (ROE) | -20.39% |
| Debt-to-equity | 0.11 |
AAnchor
| Beta (price swings) | 1.49 |
| Market cap | ₹1,270 Cr |
| Insider holding | 1.83% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is MaxCyte, Inc.'s PosiPenta score?
MaxCyte, Inc.'s PosiPenta is 52.65 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does MaxCyte, Inc. stand on the Penta Grid?
On the Penta Grid this week, MaxCyte, Inc. is Grid #239 of 837 in the Healthcare sector in United States, and Grid #1,566 of 4,000 in United States.
Which PosiPenta pillar is strongest for MaxCyte, Inc.?
Nitro (momentum), with a score of 75 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for MaxCyte, Inc.?
Anchor (stability and dividends), with a score of 36 out of 100: weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.